Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Therapies for older leukemia patients

No. 41c | 02/08/2017 | by Koh

The German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) will provide funding for a new research group at the German Cancer Research Center (DKFZ) and at the University of Freiburg and Freiburg University Medical Center. The scientists will jointly pursue fundamental and clinical research into acute myeloid leukemia (AML). The DFG will support the project with funds of approximately €4.2 million over the next three years.

© The Armed Forces Institute of Pathology (AFIP), Wikimedia Commons

AML, a malignant disease of the blood, is diagnosed each year in about 3,000 people in Germany. The disease primarily affects people over 60 years. It accounts for approximately 80 percent of acute leukemias affecting adults. The new research group called "Age-Related Epigenetic Remodeling in Acute Myeloid Leukemia" will be studying epigenetic alterations in leukemia stem cells, which occur primarily in elderly people and can lead to the onset of leukemia. The group spokesperson is Professor Dr. Michael Lübbert from the Department of Medicine I of the Medical Center - University of Freiburg. He will be responsible for coordinating the project together with Professor Dr. Christoph Plass from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg.

Epigenetics studies mechanisms of inheritance that happen without any changes in the DNA sequence. These are dynamic modifications in which changing environmental conditions such as diet, stress or medications leave epigenetic patterns. Epigenetic mechanisms regulate which genes are activated or silenced at any given time.

The scientists will be focusing primarily on the interactions between the genetic alterations in AML and the epigenome – the complete set of epigenetic patterns – in leukemia stem cells of various aging phases. In addition, the consortium aims to further develop existing epigenetic therapy approaches and implement them in the clinic as swiftly as possible, with a particular focus on the treatment of elderly persons with AML. "We currently lack effective and well-tolerated therapies particularly for AML patients at an advanced age," said Plass, who is pleased about the funding approval by the DFG. "There is a great need for research in this area. The support by the DFG will enable us to follow up on very promising approaches and possibly advance them to clinical testing stage."

The DFG provides funding for research groups and clinical research groups that team up to pursue a common research goal in order to enable them to achieve results that would usually not be possible as part of an individual funding program.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS